search
Back to results

Geniculate Artery Embolization for Knee Osteoarthritis (GAEKO)

Primary Purpose

Osteo Arthritis Knee

Status
Withdrawn
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Geniculate Artery Embolization
Sponsored by
University of Calgary
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteo Arthritis Knee focused on measuring Embolization

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Moderate to severe knee pain (visual analog scale (VAS) > 50 mm), and
  • Pain refractory for at least 3 months of conservative therapies (anti-inflammatory drugs, physical therapy, muscle strengthening or intra-articular injections), and
  • Kellgren-Lawrence grade 1, 2 or 3 on knee radiograph, and
  • MRI features of active synovitis (Synovial thickening and/or enhancement on MRI using pre-gadolinium sagittal T2-weighted/proton-density sequences and post-gadolinium T1 weighted imaging, respectively), and
  • Willing, able and mentally competent to provide written informed consent (to ensure that all study subjects demonstrate an understanding of the risks of the procedure and participate in the informed consent), and
  • Not eligible for surgical arthroplasty within 1 year of estimated procedure date

Exclusion Criteria:

  • Major surgery within the past six weeks (excluding arthroscopic/meniscal interventions), or
  • Ipsilateral knee intra-articular injection in the last 3 months, or
  • Pregnant or attempting to become pregnant during study period, or
  • Current local infection, or
  • Life expectancy less than 6 months, or
  • Known advanced atherosclerosis, or
  • Rheumatoid or seronegative arthropathies, or
  • Infectious arthritis, or
  • Prior knee surgery (excluding arthroscopic/meniscal interventions), or
  • Uncorrectable coagulopathy including international normalized ratio (INR) > 1.5 or platelets < 50,000, or
  • Iodinated contrast allergy resulting in anaphylaxis, or
  • Inability to lay supine on an angiographic table >500 lbs due to table weight limits, or
  • Renal dysfunction as defined as glomerular filtration rate < 30 mL/min/1.73m2 obtained within the past 30 days, or
  • Patients with documented noncompliance with previous medical care, or
  • Patients with certain psychiatric disorders such as schizophrenia, borderline personality disorder, uncontrolled depression, or mental/cognitive impairment that limits the individual's ability to understand the proposed therapy, or
  • Absence of synovitis on MRI

Sites / Locations

  • South Healthy Campus

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Geniculate Artery Embolization

Arm Description

Patients undergoing geniculate artery embolization. Patients will be assessed and followed post-procedurally to detect changes in knee pain and function. Medication use, adverse events and performance based tests of physical function will also be recorded. A pre-procedural MRI will be compared to a 6 month post-procedure MRI to assess for changes in synovitis and assess for complications.

Outcomes

Primary Outcome Measures

Patient Pain (mm): visual analog scale
Severity of pain as assessed by visual analog scale. The visual analog scale is a 100 mm horizontal line with 0 mm correlating with "No Pain" and 100 mm with "Worst Possible Pain". Accompanying the verbal description is an illustrative guide correlating values to facial expressions. Patients mark their responses with a single vertical line. Results will be recorded prior to the procedure and afterwards at each follow-up visit to measure for changes in knee pain.
Patient function (arbitrary units)
Knee injury and Osteoarthritis Outcome Score (KOOS) will be used to measure joint function. This is a questionnaire in which questions regarding pain, other symptoms, function in activities of daily living, function in sport and recreation and knee-related quality of life are answered to calculate subscale scores. Each subscale (symptoms, activities of daily living, sport and recreation, quality of life) is scored from 0 to 100 with 0 representing extreme symptoms and 100 indicating no symptoms). The questionnaire will be completed at follow-up evaluations to measure change in each subscale from baseline (prior to intervention). Investigators will analyze scores to determine if patient's subjective joint function changes.

Secondary Outcome Measures

Medication use (arbitrary units)
Change in number or dosage of osteoarthritis medical therapy including oral, topical medications and joint injections will be recorded. Number will be defined as total number of medications used for knee osteoarthritis. Dosage will be defined as the frequency of administration multiplied by the dose of each administration (i.e. 200 mg, 3 times daily will be scored as 600 mg daily). Values will be recorded at each follow-up visit to measure change from baseline and summarized with simple statistics (i.e. percentage of patients with a decrease in medication use).
Physical function (arbitrary units)
Change in physical function performance will be assessed with a 30 second chair stand test.
Synovitis (arbitrary units)
A semiquantifiable synovitis scoring scale on contrast enhanced MRI will be used to assess change in synovitis as proposed by Guermazi et al. in 2011. Synovial thickness will be scored semiquantifiably from grade 0 to 2 at 11 anatomical locations. Grading is calculate by meausrement of maximal synovial thickness with 2 mm or less scored as grade 0, 2-4 mm as grade 1 and > 4 mm as grade 2. Grading at each location are summed to compute a total synovitis score with a minimum score of 0 representing no synovitis and a maximal score of 22 representing severe synovitis. Investigators will compare scores calculated at a 6 month contrast enhanced MRI to those obtained prior to intervention to assess for changes in synovitis.

Full Information

First Posted
January 31, 2019
Last Updated
April 26, 2021
Sponsor
University of Calgary
search

1. Study Identification

Unique Protocol Identification Number
NCT03835988
Brief Title
Geniculate Artery Embolization for Knee Osteoarthritis
Acronym
GAEKO
Official Title
Geniculate Artery Embolization for Knee Osteoarthritis
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Withdrawn
Why Stopped
Covid department protocol prevented patient recruitment and affected funding.
Study Start Date
March 1, 2019 (Actual)
Primary Completion Date
April 1, 2021 (Actual)
Study Completion Date
December 31, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Calgary

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
A prospective cohort study to study the effectiveness and safety profile of geniculate artery embolization for the treatment of symptomatic knee osteoarthritis.
Detailed Description
Purpose: The investigators aim to determine whether geniculate artery embolization is a safe treatment for symptomatic knee osteoarthritis and confirm published reports of sustained post-procedural pain relief, improved physical function and investigate potential improvements in joint function quantitatively through imaging and targeted assessments. Participants:Twenty patients with moderate to severe knee pain, pain refractory for 3 months of conservative therapies, imaging features of symptomatic osteoarthritis and ineligible for arthroplasty for 1 year. Procedures (methods): Patients will undergo a brief clinical evaluation to verify eligibility through inclusion and exclusion criteria in addition to a comprehensive joint pain treatment history will be recorded including active analgesic and anti-inflammatory use. A pre-procedural MRI will be completed to assess the extent of their osteoarthritis, signs of active synovitis and vascular anatomy of the knee. Evaluations post geniculate artery embolization will occur at 24 hours, 1, 6 and 12 months to assess for changes in knee pain and joint function and monitor adverse events. An MRI will be performed at the 6 month visit to detect changes in synovitis and exclude complications.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteo Arthritis Knee
Keywords
Embolization

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Geniculate Artery Embolization
Arm Type
Experimental
Arm Description
Patients undergoing geniculate artery embolization. Patients will be assessed and followed post-procedurally to detect changes in knee pain and function. Medication use, adverse events and performance based tests of physical function will also be recorded. A pre-procedural MRI will be compared to a 6 month post-procedure MRI to assess for changes in synovitis and assess for complications.
Intervention Type
Device
Intervention Name(s)
Geniculate Artery Embolization
Other Intervention Name(s)
Embozene Embolic Particles, Embosphere Embolic Particles
Intervention Description
Embolization is a procedure completed by an Interventional Radiologist in which abnormal blood vessels are blocked for treatment purposes. In the case of geniculate artery embolization, abnormal blood vessels which supply your knee joint are blocked in an effort to reduce inflammation and subsequently and reduce pain and improve joint function.
Primary Outcome Measure Information:
Title
Patient Pain (mm): visual analog scale
Description
Severity of pain as assessed by visual analog scale. The visual analog scale is a 100 mm horizontal line with 0 mm correlating with "No Pain" and 100 mm with "Worst Possible Pain". Accompanying the verbal description is an illustrative guide correlating values to facial expressions. Patients mark their responses with a single vertical line. Results will be recorded prior to the procedure and afterwards at each follow-up visit to measure for changes in knee pain.
Time Frame
1 year
Title
Patient function (arbitrary units)
Description
Knee injury and Osteoarthritis Outcome Score (KOOS) will be used to measure joint function. This is a questionnaire in which questions regarding pain, other symptoms, function in activities of daily living, function in sport and recreation and knee-related quality of life are answered to calculate subscale scores. Each subscale (symptoms, activities of daily living, sport and recreation, quality of life) is scored from 0 to 100 with 0 representing extreme symptoms and 100 indicating no symptoms). The questionnaire will be completed at follow-up evaluations to measure change in each subscale from baseline (prior to intervention). Investigators will analyze scores to determine if patient's subjective joint function changes.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Medication use (arbitrary units)
Description
Change in number or dosage of osteoarthritis medical therapy including oral, topical medications and joint injections will be recorded. Number will be defined as total number of medications used for knee osteoarthritis. Dosage will be defined as the frequency of administration multiplied by the dose of each administration (i.e. 200 mg, 3 times daily will be scored as 600 mg daily). Values will be recorded at each follow-up visit to measure change from baseline and summarized with simple statistics (i.e. percentage of patients with a decrease in medication use).
Time Frame
1 year
Title
Physical function (arbitrary units)
Description
Change in physical function performance will be assessed with a 30 second chair stand test.
Time Frame
1 year
Title
Synovitis (arbitrary units)
Description
A semiquantifiable synovitis scoring scale on contrast enhanced MRI will be used to assess change in synovitis as proposed by Guermazi et al. in 2011. Synovial thickness will be scored semiquantifiably from grade 0 to 2 at 11 anatomical locations. Grading is calculate by meausrement of maximal synovial thickness with 2 mm or less scored as grade 0, 2-4 mm as grade 1 and > 4 mm as grade 2. Grading at each location are summed to compute a total synovitis score with a minimum score of 0 representing no synovitis and a maximal score of 22 representing severe synovitis. Investigators will compare scores calculated at a 6 month contrast enhanced MRI to those obtained prior to intervention to assess for changes in synovitis.
Time Frame
1 year
Other Pre-specified Outcome Measures:
Title
Patient complications (arbitrary units)
Description
The number of complications or adverse events with associated descriptions from geniculate artery embolization will be recorded. Results will be summarized using simple statistics.
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Moderate to severe knee pain (visual analog scale (VAS) > 50 mm), and Pain refractory for at least 3 months of conservative therapies (anti-inflammatory drugs, physical therapy, muscle strengthening or intra-articular injections), and Kellgren-Lawrence grade 1, 2 or 3 on knee radiograph, and MRI features of active synovitis (Synovial thickening and/or enhancement on MRI using pre-gadolinium sagittal T2-weighted/proton-density sequences and post-gadolinium T1 weighted imaging, respectively), and Willing, able and mentally competent to provide written informed consent (to ensure that all study subjects demonstrate an understanding of the risks of the procedure and participate in the informed consent), and Not eligible for surgical arthroplasty within 1 year of estimated procedure date Exclusion Criteria: Major surgery within the past six weeks (excluding arthroscopic/meniscal interventions), or Ipsilateral knee intra-articular injection in the last 3 months, or Pregnant or attempting to become pregnant during study period, or Current local infection, or Life expectancy less than 6 months, or Known advanced atherosclerosis, or Rheumatoid or seronegative arthropathies, or Infectious arthritis, or Prior knee surgery (excluding arthroscopic/meniscal interventions), or Uncorrectable coagulopathy including international normalized ratio (INR) > 1.5 or platelets < 50,000, or Iodinated contrast allergy resulting in anaphylaxis, or Inability to lay supine on an angiographic table >500 lbs due to table weight limits, or Renal dysfunction as defined as glomerular filtration rate < 30 mL/min/1.73m2 obtained within the past 30 days, or Patients with documented noncompliance with previous medical care, or Patients with certain psychiatric disorders such as schizophrenia, borderline personality disorder, uncontrolled depression, or mental/cognitive impairment that limits the individual's ability to understand the proposed therapy, or Absence of synovitis on MRI
Facility Information:
Facility Name
South Healthy Campus
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T3M 1M4
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
14613558
Citation
Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis. Health Qual Life Outcomes. 2003 Nov 3;1:64. doi: 10.1186/1477-7525-1-64.
Results Reference
background
PubMed Identifier
21187293
Citation
Guermazi A, Roemer FW, Hayashi D, Crema MD, Niu J, Zhang Y, Marra MD, Katur A, Lynch JA, El-Khoury GY, Baker K, Hughes LB, Nevitt MC, Felson DT. Assessment of synovitis with contrast-enhanced MRI using a whole-joint semiquantitative scoring system in people with, or at high risk of, knee osteoarthritis: the MOST study. Ann Rheum Dis. 2011 May;70(5):805-11. doi: 10.1136/ard.2010.139618. Epub 2010 Dec 27.
Results Reference
background

Learn more about this trial

Geniculate Artery Embolization for Knee Osteoarthritis

We'll reach out to this number within 24 hrs